Wong Andrew K, Keeney Lauren Georgiades, Chen Liting, Williams Rebekah, Liu Jiabin, Elkassabany Nabil M
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Pain Med. 2016 Dec;17(12):2397-2403. doi: 10.1093/pm/pnw057. Epub 2016 Apr 13.
This study aims to assess diaphragmatic excursion and measure pulmonary functions as measures of the degree to which the phrenic nerve is blocked after ISB with two different concentrations of ropivacaine: 0.2% and 0.1%.
Randomized, double-blinded study.
Ambulatory surgical facility.
Fifty patients undergoing shoulder arthroscopy for rotator cuff repair.
Patients were randomized to receive ultrasound-guided ISB with 20 mL of either 0.2% or 0.1% ropivacaine. Diaphragmatic excursion was measured using M-mode ultrasound. Pulmonary functions were assessed by portable spirometer. Additional outcome data included oxygen saturation in post-anesthesia care unit (PACU), pain scores, quality of recovery scores (QOR), and opioid consumption over 72 hour period after surgery.
Forced vital capacity (FVC) was significantly reduced 30 minutes after block placement and in PACU in the 0.2% group when compared with the 0.1% group (P = 0.04, P = 0.03, respectively). Forced expiratory volume (FEV1) was also significantly decreased in the 0.2% group in PACU when compared with the 0.1% group (P = 0.04). There were no significant differences in pain scores, length of stay, and total opioid consumption in PACU. Patients who received 0.2% ropivacaine had a longer block duration (18 vs 11.9 hours, P = 0.04) and used less opioid in the 72 hours after surgery (55 mg vs 102 mg codeine equivalents, P = 0.02), when they were compared to their counterparts who received 0.1% for their block.
0.1% ropivacaine may impair pulmonary function less than 0.2% ropivacaine. The clinical significance of these differences needs to be further studied.
本研究旨在评估膈活动度并测量肺功能,以此作为在肌间沟阻滞(ISB)后使用两种不同浓度罗哌卡因(0.2%和0.1%)时膈神经被阻滞程度的指标。
随机双盲研究。
门诊手术机构。
50例因肩袖修复接受肩关节镜检查的患者。
患者被随机分配接受超声引导下的肌间沟阻滞,注射20毫升0.2%或0.1%的罗哌卡因。使用M型超声测量膈活动度。通过便携式肺活量计评估肺功能。其他结果数据包括麻醉后护理单元(PACU)的血氧饱和度、疼痛评分、恢复质量评分(QOR)以及术后72小时内的阿片类药物消耗量。
与0.1%组相比,0.2%组在阻滞放置后30分钟及在PACU时用力肺活量(FVC)显著降低(分别为P = 0.04,P = 0.03)。与0.1%组相比,0.2%组在PACU时的用力呼气量(FEV1)也显著降低(P = 0.04)。PACU中的疼痛评分、住院时间和阿片类药物总消耗量无显著差异。与接受0.1%罗哌卡因进行阻滞的患者相比,接受0.2%罗哌卡因的患者阻滞持续时间更长(18小时对11.9小时,P = 0.04),且术后72小时内使用的阿片类药物更少(55毫克对102毫克可待因当量,P = 0.02)。
0.1%罗哌卡因对肺功能的损害可能小于0.2%罗哌卡因。这些差异的临床意义需要进一步研究。